Celsion Commences Pivotal Phase I/II Study Of ThermoDox(R) In The Treatment Of Recurrent Chest Wall Breast Cancer

News — By on February 12, 2009 at 6:00 am

Celsion Corporation (NASDAQ: CLSN), an oncology company dedicated to the development and commercialization of therapies for difficult-to-treat cancers, announced today that it has initiated a pivotal Phase I/II study of ThermoDox® in combination with hyperthermia, or heat, to treat recurrent chest wall breast cancer, a disease with a very poor patient prognosis and limited treatment options.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback